Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

125.09 -1.73 (-1.36%)
Streaming Delayed Price Updated: 1:52 PM EDT, May 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 498,118
Open 127.03
Bid (Size) 124.98 (3)
Ask (Size) 125.20 (2)
Prev. Close 126.82
Today's Range 124.07 - 127.94
52wk Range 61.28 - 159.89
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Shares of Sarepta Therapeutics Are Dropping Wednesday
The FDA told the company that a review of a new therapy will take nearly a month longer. 
Via The Motley Fool
Why America's Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares jumped 209.1% to $0.5622 after the United States Patent and Trademark Office granted the company a patent for certain medical systems and methods. 
Via Benzinga

Performance

YTD
+0.20%
+0.20%
1 Month
-0.02%
-0.02%
3 Month
+5.89%
+5.89%
6 Month
+5.89%
+5.89%
1 Year
+71.78%
+71.78%

More News

Read More
Sarepta Therapeutics Inc. (NASDAQ: SRPT) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
Why Sarepta Therapeutics Stock Is Skyrocketing Today
Via The Motley Fool
Why Sarepta Therapeutics Stock Faded This Week
Via The Motley Fool
Sarepta: The AdCom Documents Enter The Discussion
Via Talk Markets
2 Under-the-Radar Biotech Stocks to Buy in 2023
Via The Motley Fool
Sarepta Therapeutics Dives On An Unexpected Hold-Up For Its Gene Therapy
Via Investor's Business Daily
Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001
From Sarepta Therapeutics, Inc.
Via Business Wire
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
Via MarketBeat
Exposures Product Safety
Why These 3 Nasdaq Stocks Buckled Today
Via The Motley Fool
Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy
Via MarketBeat
Exposures Product Safety
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Is Sarepta (SRPT) Stock Up 29% Today?
Via InvestorPlace
Sarepta Therapeutic Shares Surge 25% Following Favorable Gene Therapy Vote; Analyst Anticipates Huge Earnings Swing In 2024
Via Benzinga
US Stocks Mixed; NY Manufacturing Activity Shrinks In May
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Benzinga Pro's Top 5 Stocks To Watch For Monday, May 15, 2023: TSLA, SRPT, TJX, MNDY, LTRY
Via Benzinga
Why Sarepta Therapeutics Stock Is Soaring Today
Via Benzinga
FDA AdComm Narrowly Supports Approval Of Sarepta's Gene Therapy For Rare Neuromuscular Disorder
Via Benzinga
2 Supercharged Growth Stocks to Buy Right Now
Via The Motley Fool
Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Halted As FDA Mulls Its Highly Anticipated Gene Therapy
Via Investor's Business Daily
FDA Staff Raises Issues For Sarepta's Duchenne Gene Therapy Data, Analyst Says Issues Known, Expects Positive Vote
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.